The global Cell & Gene Therapy Manufacturing Services market gathered revenue around USD 6.9 Billion in 2020 and market is set to grow USD 15.2 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 13.2% during the prediction period 2021 to 2027.
Growth Factors:
The market Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.
The cell & gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing on the basis of application. The clinical manufacturing segment accounted for the highest growth rate in the cell & gene therapy manufacturing services market during the forecast period. This segment's high growth rate can be attributed to increasing government funding for cancer research and the increasing number of cell & gene therapy clinical trials.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Cell & Gene Therapy Manufacturing Services market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Cell & Gene Therapy Manufacturing Services market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
Report Coverage
Report Scope | Details |
Market Size | USD 15.2 Billion by 2027 |
Growth Rate | CAGR of 13.2% From 2021 to 2027 |
Base Year | 2020 |
Forecast Period | 2021 to 2027 |
Historic Data | 2017 to 2020 |
Report coverage | Growth Factors, Revenue Status, Competitive Landscape, and Future Trends |
Segments Covered | Type, Indication, Application, End User and Region |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Companies Mentioned | Thermo Fisher Scientific , Merck KGaA , Charles River Laboratories , Lonza , Catalent , WuXi AppTec , Takara Bio Inc. , Nikon Corporation , FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd. , Oxford Biomedica plc , and Cell and Gene Therapy Catapult . |
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Cell & Gene Therapy Manufacturing Services market report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
North America dominated the cell and gene therapy manufacturing market and accounted for the largest revenue share of 42.0% in 2020. A substantial number of ongoing clinical trials coupled with the rising engagement of companies in the R&D of gene and cell therapy is the major driving factor for regional market growth. North America pegged the first rank for exhibiting the highest number of gene therapy clinical trials with the presence of more than 400 companies in the region actively engaged in the development of cell and gene therapy products for various diseases.
In Europe, multiple new collaborative research and innovation projects were launched, under Horizon 2020 initiative. These projects include viral vector-based gene therapy trials for rare conditions. This is expected to drive the growth of cell and gene therapy manufacturing services across the European nations. A strong facility network coupled with a strong workforce in European countries is anticipated to further fuel the market growth.
On the other hand, Asia Pacific countries are emerging as strong contenders in this space. The establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs are the key driving factors for the emergence of Asian markets. Moreover, China is recognized as the fast-growing market for cell and gene therapy development and has been ranked second in terms of clinical trials across the globe.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Significant Market Participants Operational in the Cell & Gene Therapy Manufacturing Services Market are: Thermo Fisher Scientific , Merck KGaA , Charles River Laboratories , Lonza , Catalent , WuXi AppTec , Takara Bio Inc. , Nikon Corporation , FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd. , Oxford Biomedica plc , and Cell and Gene Therapy Catapult .
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Cell & gene therapy manufacturing services Market, by Type
Cell & gene therapy manufacturing services Market, by Indication
Cell & gene therapy manufacturing services Market, by Application
Cell & gene therapy manufacturing services Market, by End User
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Highlights of the Report:
Research Methodology
A unique research methodology has been utilized by Nova one advisor to conduct comprehensive research on the growth of the global Cell & Gene Therapy Manufacturing Services market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Nova one advisor employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of methodology employed for all our studies include:
Preliminary data mining
Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For comprehensive understanding of the market, it is essential to understand the complete value chain and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.
Statistical model
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise.
Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of technology landscape, regulatory frameworks, economic outlook and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:
We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.
Primary validation
This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, on face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation, but also provide critical insights into the market, current business scenario and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:
The key objectives of primary research are as follows:
Secondary Validation
Secondary research sources referred to by analysts during the production of the global Cell & Gene Therapy Manufacturing Services market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of Nova one advisor’s study on the Cell & Gene Therapy Manufacturing Services market as primary methods.
The study objectives of this report are: